Upstream Bio to Participate in Upcoming December Investor Conferences
Rhea-AI Summary
Upstream Bio (Nasdaq: UPB) announced that CEO Rand Sutherland, MD will participate in two investor conferences in December 2025: a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York on Tuesday, December 2, 2025 at 4:30 p.m. ET, and a fireside chat at the 8th Annual Evercore Healthcare Conference in Miami on Thursday, December 4, 2025 at 10:25 a.m. ET.
Live webcasts will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of each presentation, and replays will be posted after the events.
Positive
- None.
Negative
- None.
News Market Reaction 22 Alerts
On the day this news was published, UPB gained 10.67%, reflecting a significant positive market reaction. Argus tracked a peak move of +10.5% during that session. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $152M to the company's valuation, bringing the market cap to $1.58B at that time.
Data tracked by StockTitan Argus on the day of publication.
WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in December:
- Piper Sandler 37th Annual Healthcare Conference, New York, NY
Tuesday, December 2, 2025, Fireside Chat – 4:30 p.m. ET - 8th Annual Evercore Healthcare Conference, Miami, FL
Thursday, December 4, 2025, Fireside Chat – 10:25 a.m. ET
Live webcasts of the presentations will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of the event. A replay of the webcasts will be posted on the Company's website following the presentations.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Upstream Bio is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Upstream Bio has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com
FAQ
When will Upstream Bio (UPB) present at the Piper Sandler conference?
What time is Upstream Bio (UPB) scheduled to speak at Evercore Healthcare on December 4, 2025?
How can investors watch Upstream Bio (UPB) CEO Rand Sutherland's presentations?
Will there be a replay of the Upstream Bio (UPB) conference presentations?
Who will represent Upstream Bio (UPB) at the December 2025 investor conferences?
Which cities host Upstream Bio's December 2025 investor events for UPB?
